Document is current

Article History

Received: 13 February 2022

Revised: 29 May 2022

Accepted: 8 June 2022

First Online: 29 June 2022

Competing interests

: SAG receives research funding from Miltenyi Biotec, Takeda, Celgene, Amgen, Sanofi, Johnson and Johnson and Actinium and is on the advisory boards for: Kite, Celgene, Sanofi, Novartis, Johnson and Johnson, Amgen, Takeda, Jazz, and Actinium. JH reports receiving honoraria from Curio Science, Amgen, AdBoards, GSK, Axxess Network, IntelliSphere and Janssen. SJ has served as a consultant for BMS, Janssen Pharmaceuticals, Karyopharm Therapeutics, Legend Biotech, Sanofi and Takeda. SK reports research funding to Mayo from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates. He has served as a consultant for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and Oncopeptides. SL has served as a speaker for PerView, Clinical Care Options and RedMed, as a consultant for Caelum Bioscience, Pfizer, Takeda, Natara, Janssen, Celularity, Abbvie, GSK, Takeda, Karyopharm, Sanofi and Oncopetide, owns stock in Caelum Bioscience, Magenta and Poseida and has received research funding from Karyopharm and Sanofi. NSR has served as a consultant for BMS, Janssen, Pfizer, Amgen. Takeda, Abbvie and Sanofi, on the scientific advisory board for Caribou Bioscience and Immuneel and has received research funding from Bluebird Bio. PGR has received payments/honoraria from Oncopeptides, Celgene/BMS, Takeda, Karyopharm, Janssen, Sanofi, Secura Bio, GSK, Regeneron, AstraZeneca and Protocol Intelligence and reports interests in Oncopeptides, Celgene/BMS, Takeda and Karyopharm. AJY has served as a consultant for Adaptive, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Oncopeptides, Regeneron, Sanofi, and Takeda. LB, NSC, BF, AH, RFL, PLM, AR, and EIS declare no competing interests.